PepSets™ Peptide Libraries ❭

PepSets™ can be supplied with a precise length and offset designed to best suit the user’s assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence to adapt the usage for any experimental purpose.

In recent years, PepSets™ have had tremendous successes in the immunology sector for vaccine and drug development. These versatile molecular tools have further applications in dozens of fields, including epitope mapping and structure-activity studies.  

  • Discover crucial residues with an Alanine Scan Library 
  • Map epitopes with an Overlapping Peptide Library 
  • Narrow down the shortest active sequences with a Truncated Peptide Library

Fast & Reliable

Mimotopes is the founder of peptide libraries. Across the 35 years since its inception, the technology and its userbase have developed side-by-side to make PepSets™ an unrivaled juggernaut in research today.

Hundreds of peptides are synthesized simultaneously with Mimotopes’ exclusive parallel synthesis technology. Thanks to a rapid production cycle, peptide libraries reach their users fast, aiming to never delay critical experiments.

Contact us today for a quote!

Australia

☎ +61 3 9565 1111
✉ australia@mimotopes.com

North and South America

☎ +1 651 603 0909
✉ useast@mimotopes.com
uswest@mimotopes.com

Asia

☎ +61 3 9565 1111
✉ asia@mimotopes.com

UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547
✉ europe@mimotopes.com

Go to article: Home | Left in limbo: When pharma halts rare disease researchGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: FaravelliGo to article: In DepthGo to article: Left in limbo: When pharma halts rare disease research Go to article: Capturing the genAI boom for drug developmentGo to article: Too much data: a burden or a blessing? Go to article: South Korea seeks to accelerate drug reimbursement administration process Go to article: Sponsors must take on FDA’s diversity guidance to improve community trust Go to article: DelSiTech Company InsightGo to article: Thematic Take: CybersecurityGo to article: Thematic Take: contentsGo to article: Foreword: Cybersecurity in the age of AI Go to article: Navigating the AI-driven cybersecurity landscapeGo to article: Key trends impacting cybersecurity Go to article: Timeline: a history of cybersecurity Go to article: Explainer: The most common types of cyberattacks Go to article: The impact of cybersecurity on healthcareGo to article: Case studies: cybersecurity in healthcare Go to article: Leading cybersecurity adopters and providers in healthcareGo to article: AI attacks now ‘the main cybersecurity concern’ for businesses across sectors Go to article: The state of cybersecurity: AI and geopolitics mean a bigger threat than ever Go to article: Companies’ own AI applications are ‘a huge cybersecurity problem’ Go to article: How healthcare cybercrime is predicted to escalate Go to article: The lasting impacts of the pandemic on cybersecurity in healthcare Go to article: Cyberattacks on healthcare: Russia’s tool for mass disruption Go to article: Traceability technologies tighten supply chain fakery Go to article: Deal activity related to cybersecurity in the pharma industry since 2021 Go to article: Regulators must protect the cybersecurity market from a private equity takeover Go to article: GlobalData Thematic IntelligenceGo to article: Sponsored SupplementsGo to article: XylemGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue